Literature DB >> 26542992

Debate: Molecular cardiac imaging is ready for the prime time con between wishful thinking and reality.

Ignasi Carrió1.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26542992     DOI: 10.1007/s12350-015-0124-5

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  13 in total

1.  A definition of molecular imaging.

Authors:  David A Mankoff
Journal:  J Nucl Med       Date:  2007-06       Impact factor: 10.057

2.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

Authors:  Gilles Montalescot; Udo Sechtem; Stephan Achenbach; Felicita Andreotti; Chris Arden; Andrzej Budaj; Raffaele Bugiardini; Filippo Crea; Thomas Cuisset; Carlo Di Mario; J Rafael Ferreira; Bernard J Gersh; Anselm K Gitt; Jean-Sebastien Hulot; Nikolaus Marx; Lionel H Opie; Matthias Pfisterer; Eva Prescott; Frank Ruschitzka; Manel Sabaté; Roxy Senior; David Paul Taggart; Ernst E van der Wall; Christiaan J M Vrints; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Juhani Knuuti; Marco Valgimigli; Héctor Bueno; Marc J Claeys; Norbert Donner-Banzhoff; Cetin Erol; Herbert Frank; Christian Funck-Brentano; Oliver Gaemperli; José R Gonzalez-Juanatey; Michalis Hamilos; David Hasdai; Steen Husted; Stefan K James; Kari Kervinen; Philippe Kolh; Steen Dalby Kristensen; Patrizio Lancellotti; Aldo Pietro Maggioni; Massimo F Piepoli; Axel R Pries; Francesco Romeo; Lars Rydén; Maarten L Simoons; Per Anton Sirnes; Ph Gabriel Steg; Adam Timmis; William Wijns; Stephan Windecker; Aylin Yildirir; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2013-08-30       Impact factor: 29.983

3.  2012 FDA drug approvals.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

4.  Radiopharmaceuticals are special, but is this recognized? The possible impact of the new Clinical Trials Regulation on the preparation of radiopharmaceuticals.

Authors:  C Decristoforo; I Penuelas; P Elsinga; J Ballinger; A D Winhorst; A Verbruggen; F Verzijlbergen; A Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-11       Impact factor: 9.236

5.  2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC).

Authors:  Raimund Erbel; Victor Aboyans; Catherine Boileau; Eduardo Bossone; Roberto Di Bartolomeo; Holger Eggebrecht; Arturo Evangelista; Volkmar Falk; Herbert Frank; Oliver Gaemperli; Martin Grabenwöger; Axel Haverich; Bernard Iung; Athanasios John Manolis; Folkert Meijboom; Christoph A Nienaber; Marco Roffi; Hervé Rousseau; Udo Sechtem; Per Anton Sirnes; Regula S von Allmen; Christiaan J M Vrints
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

6.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Authors:  John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher
Journal:  Eur Heart J       Date:  2012-05-19       Impact factor: 29.983

Review 7.  Positron emission tomography tracers for imaging angiogenesis.

Authors:  Roland Haubner; Ambros J Beer; Hui Wang; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

8.  Open access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicine.

Authors:  Patrick A Gladding; Andrew Cave; Mehran Zareian; Kevin Smith; Jagir Hussan; Peter Hunter; Folarin Erogbogbo; Zoraida Aguilar; David S Martin; Eugene Chan; Margie L Homer; Abhijit V Shevade; Mohammad Kassemi; James D Thomas; Todd T Schlegel
Journal:  J Pers Med       Date:  2013-08-21

9.  The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology.

Authors:  Paulus Kirchhof; Karin R Sipido; Martin R Cowie; Thomas Eschenhagen; Keith A A Fox; Hugo Katus; Stefan Schroeder; Heribert Schunkert; Silvia Priori
Journal:  Eur Heart J       Date:  2014-08-22       Impact factor: 29.983

10.  18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial.

Authors:  Nikhil V Joshi; Alex T Vesey; Michelle C Williams; Anoop S V Shah; Patrick A Calvert; Felicity H M Craighead; Su Ern Yeoh; William Wallace; Donald Salter; Alison M Fletcher; Edwin J R van Beek; Andrew D Flapan; Neal G Uren; Miles W H Behan; Nicholas L M Cruden; Nicholas L Mills; Keith A A Fox; James H F Rudd; Marc R Dweck; David E Newby
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

View more
  1 in total

Review 1.  Review of Cardiovascular Imaging in the Journal of Nuclear Cardiology in 2016. Part 1 of 2: Positron Emission Tomography, Computed Tomography and Magnetic Resonance.

Authors:  Wael AlJaroudi; Fadi G Hage
Journal:  J Nucl Cardiol       Date:  2017-02-13       Impact factor: 5.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.